Cadrenal Therapeutics, Inc. (CVKD) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.11

From 52W high−92.32%

Volume86058.00

Market cap$3.89M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.11

From 52W high

−92.32%

Volume

86058.00

Market cap

$3.89M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

30.0

MomentumView details →

1D Return

−2.68%

YTD Return

−83.19%

SummaryUpdated Jun 1, 2026

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Ponte Vedra, Florida. The company went public in January 2023 and focuses exclusively on developing a single therapeutic candidate called Tecarfarin, designed to address a critical unmet medical need in patients with end-stage kidney disease who also suffer from atrial fibrillation.

Ask drillr about Cadrenal Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−282.13%

ROA (TTM)

−206.55%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+44.88%

FCF YoY

+12.95%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+23.94%

EBITDA YoY

+18.02%

MomentumView details →

1D Return

−2.68%

YTD Return

−83.19%

1Y Return

−91.34%

RSI (14)

30.0

vs 50D SMA

−34.95%

vs 200D SMA

−77.50%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.73x

Quick Ratio

3.73x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.14

EPS Surprise

19.72%

Beats (12Q)

3/12

Next Q EPS Est

−$0.91

Avg Surprise (4Q)

0.72%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−11.54M

Op. CF (TTM)

−10.16M

Next earningsNov 9, 2026 →

Latest newsMore news →

Cadrenal Therapeutics announced positive feedback from an FDA Type D meeting held on July 28, 2026, regarding its Phase 3 registration study of CAD-1005 for heparin-induced thrombocytopenia.20d ago

Cadrenal Therapeutics announced that Matthew K. Szot departed as Chief Financial Officer by mutual agreement, effective May 28, 2026, and appointed Quang X. Pham as interim Chief Financial Officer and interim Principal Accounting Officer, effective the same date.110d ago

Similar companies

PMGC Holdings Inc.ELAB Mustang Bio, Inc.MBIO Jupiter Neurosciences, Inc.JUNS VivoSim Labs, Inc.VIVS BioRestorative Therapies, Inc.BRTX Revelation Biosciences, Inc.REVB Find similar companies →

Latest newsMore news →

Cadrenal Therapeutics announced positive feedback from an FDA Type D meeting held on July 28, 2026, regarding its Phase 3 registration study of CAD-1005 for heparin-induced thrombocytopenia.20d ago Cadrenal Therapeutics announced that Matthew K. Szot departed as Chief Financial Officer by mutual agreement, effective May 28, 2026, and appointed Quang X. Pham as interim Chief Financial Officer and interim Principal Accounting Officer, effective the same date.110d ago